Cargando…

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer

SIMPLE SUMMARY: In almost all patients, the proliferation and growth of prostate cancer is driven by the androgen receptor. Given this critical role, inhibiting the androgen receptor is the standard of care following surgery or radiotherapy. However, the effectiveness of current anti-androgen therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ban, Fuqiang, Leblanc, Eric, Cavga, Ayse Derya, Huang, Chia-Chi Flora, Flory, Mark R., Zhang, Fan, Chang, Matthew E. K., Morin, Hélène, Lallous, Nada, Singh, Kriti, Gleave, Martin E., Mohammed, Hisham, Rennie, Paul S., Lack, Nathan A., Cherkasov, Artem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304761/ https://www.ncbi.nlm.nih.gov/pubmed/34298700 http://dx.doi.org/10.3390/cancers13143488

Ejemplares similares

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
por: Lallous, Nada, et al.
Publicado: (2013)

Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor
por: Radaeva, Mariia, et al.
Publicado: (2021)

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors
por: Radaeva, Mariia, et al.
Publicado: (2022)

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
por: Lallous, Nada, et al.
Publicado: (2016)

Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies
por: Snow, Oliver, et al.
Publicado: (2020)

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients
por: Lallous, Nada, et al.
Publicado: (2021)

20(S)-protopanaxadiol regio-selectively targets androgen receptor: anticancer effects in castration-resistant prostate tumors
por: Ben-Eltriki, Mohamed, et al.
Publicado: (2018)

Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer
por: Ton, Anh-Tien, et al.
Publicado: (2020)

Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer
por: Carabet, Lavinia A., et al.
Publicado: (2019)

Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression
por: Zhang, Fan, et al.
Publicado: (2022)

Computer-Aided Ligand Discovery for Estrogen Receptor Alpha
por: Bafna, Divya, et al.
Publicado: (2020)

Androgen receptor-binding sites are highly mutated in prostate cancer
por: Morova, Tunç, et al.
Publicado: (2020)

In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α
por: Singh, Kriti, et al.
Publicado: (2015)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer
por: Ton, Anh-Tien, et al.
Publicado: (2022)

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers
por: Singh, Kriti, et al.
Publicado: (2018)

Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner
por: Tam, Kevin J., et al.
Publicado: (2016)

Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
por: Sekine, Yoshitaka, et al.
Publicado: (2021)

PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells
por: Liu, Wei, et al.
Publicado: (2021)

Functional mapping of androgen receptor enhancer activity
por: Huang, Chia-Chi Flora, et al.
Publicado: (2021)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Dominant-Negative Androgen Receptor Inhibition of Intracrine Androgen-Dependent Growth of Castration-Recurrent Prostate Cancer
por: Titus, Mark A., et al.
Publicado: (2012)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

Androgen regulation of the androgen receptor coregulators
por: Urbanucci, Alfonso, et al.
Publicado: (2008)

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
por: Moll, J. Matthijs, et al.
Publicado: (2022)

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer
por: Pollock, Julie A., et al.
Publicado: (2016)

Androgen Receptor-Mediated Transcription in Prostate Cancer
por: Özturan, Doğancan, et al.
Publicado: (2022)

SIRNA-Directed In Vivo Silencing of Androgen Receptor Inhibits the Growth of Castration-Resistant Prostate Carcinomas
por: Compagno, Daniel, et al.
Publicado: (2007)

Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription
por: Jia, Lin, et al.
Publicado: (2018)

Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

Computer-Aided Discovery of Small Molecule Inhibitors of Transcriptional Activity of TLX (NR2E1) Nuclear Receptor
por: Dueva, Evgenia, et al.
Publicado: (2018)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022)

The androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens
por: Schweizer, Liang, et al.
Publicado: (2008)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_g9iqb98bo0e9ubkiiia5c32k0d